CoChat

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation

Open access
Arnold, Rudolf, Chen, Yuan-Jia, Costa, Frederico, Falconi, Massimo, Gross, David, Grossman, Ashley B., Hyrdel, Rudolf, Kos-Kudła, Beata, Salazar, Ramon, Plöckinger, Ursula · 2009 · Neuroendocrinology
Cited by 145

The DOI matches its Crossref record.

Abstract

The documentation of patients with neuroendocrine tumors should include the most relevant data characterizing an individual patient from the first contact with their physician/hospital until their last presentation during follow-up. The documentation should be both simple but nevertheless as complete as possible and should include basic demographic details to identify a specific patient, tumor histology and biology, disease history, course of the disease, diagnostic tests and therapeutic interventions. This information is essential for treatment and follow-up strategies adjusted to the specific features of the tumor of the patient. Furthermore, standardized documentation acts as a key precondition to learn more about patients with specific tumor subtypes and regarding the impact of treatment modalities on the course of the disease. In the present clinical setting, the timing of data collection and content of documented data vary considerably. Therefore, comparison of data from different centers is frequently hampered by lack of data uniformity.During the ENETS Standards of Care Conference organized in Mallorca in 2007, a group of physicians with extensive experience in the clinical care of patients with benign and malignant gastro-entero-pancreatic (GEP) neuroendocrine tumors met to produce proposals for the unified collection of data and suggested time intervals for follow-up investigations. These guidelines recognize the diversity of tumor subtypes, the actual WHO and TNM tumor classifications, the individual clinical course of the disease as well as the resource implications relevant to the growing costs of the European healthcare systems. Particular attention was paid to recommend only those investigations which would have a significant impact on further therapeutic strategies.The panel agreed that the following 5 categories best define the different tumor entities observed in the clinical setting. The categories follow the recent WHO classification [1, 2] as well as the ENETS recommendations for TNM staging [3, 4] in order to better compare data from different centers.Insulinomas and small, benign tumors (T1 endocrine tumors of the stomach, rectum and appendix, ‘carcinoids’) were categorized separately. They belong to the most frequent benign endocrine tumor entities and require a less intensive follow-up compared to malignant variants.• Benign insulinoma (T1 <2 cm)• Endoscopically resectable benign (T1 <1 cm) neuroendocrine tumor (carcinoid) of the stomach, duodenum and rectum• Appendiceal carcinoid (T1 <2 cm)• T2 gastric neuroendocrine tumor >1 cm invading muscularis propria or subserosa• T2 (>1 cm) tumors of the duodenum/ampulla/proximal jejunum; duodenal gastrinomas and midgut carcinoids which are usually <1 cm (T1) and confined to the submucosa are frequently malignant and belong to category III.3• T2 (>2 cm) tumors limited to the pancreas• Appendiceal carcinoid 1–2 cm(a) G1: well-differentiated, Ki-67 <2%• T1–T2 duodenal gastrinomas• T1–T3 tumors of the lower jejunum, ileum• T2–T3 tumors of the appendix • T2–T3 tumors of colon and rectum• T2–T3 tumors of the stomach, duodenum, pancreas(a) G1: well-differentiated, Ki-67 <2%(b) G2: well-differentiated, Ki-67 2–20%(c) G3: poorly differentiated• All localizations(a) G1: well-differentiated, Ki-67 <2%(b) G2: well-differentiated, Ki-67 2–20%(c) G3: poorly differentiatedDocumentation of each patient should encompass:• Patient identification and basic demographic details• General health score (Karnofsky status)• Patient’s history: onset, extent and severity of tumor-specific symptoms, concomitant diseases, family history for endocrine tumors, metachronous or synchronous malignancies• Clinical diagnosis• Preceding biochemical and imaging procedures• Histopathological diagnosis including WHO and TNM classification and proliferation index Ki-67• Preceding treatment(s)Tumor-specific follow-up investigations are mainly based on imaging procedures and tumor markers. However, an expert physician who is in charge of an individual patient is able to judge the patient’s general health and even prognosis by a careful history and examination, assessment of weight loss, muscular mass and global heart function in cases of the carcinoid syndrome and possible carcinoid cardiac disease. However, these items are difficult to compare inter- and intra-individually and should be supported where possible by ‘objective’ procedures such as imaging methods and serum/plasma tumor markers.Current imaging procedures encompass abdominal ultrasound with or without contrast medium, endoscopy, endoscopic ultrasound, CT, MRI, octreotide scintigraphy (Octreoscan®) and in some centers PET imaging with different tracers. Procedure-specific expertise frequently determines the choice of imaging procedure. Accordingly, abdominal ultrasound may be recommended for follow-up if documentation allows one to compare findings obtained during different follow-up visits, although many would now rely o

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000225952

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Arnold, R., Chen, Y.-J., Costa, F., Falconi, M., Gross, D., Grossman, A. B., Hyrdel, R., Kos-Kudła, B., Salazar, R., & Plöckinger, U.
Venue
Neuroendocrinology
Publisher
S. Karger AG
Published
2009
Volume
90
Issue
2
Pages
227-233
ISSN
  • 0028-3835 (ISSN-L)
  • 1423-0194
OpenAlex
W2150671437
Cited by
145
References
0
FWCI
5.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.